Editorial note: TotalCareMedical.com is an independent health and wellness research publication. We are not a medical practice and do not provide medical advice. This article compares two compounded GLP-1 telehealth platforms — Refills and SynergyRx — on the dimensions that matter for consumer evaluation. Compounded GLP-1 medications dispensed through either platform are not FDA-approved finished drug products. The FDA has not evaluated these compounded medications for safety, quality, or efficacy. Anyone considering GLP-1 therapy should consult a qualified healthcare provider about individual eligibility, contraindications, and risks. Individual results vary.
Refills and SynergyRx are two of the more visible compounded GLP-1 telehealth platforms operating in the United States right now. Both market direct-to-consumer access to compounded semaglutide and tirzepatide along with brand-name FDA-approved options. Both use the now-standard three-entity structure: technology platform, partner clinician network, dispensing pharmacy partners. Both target a similar consumer profile.
The platforms are not identical, though. Pricing structure differs meaningfully. Pharmacy partnerships are different. Clinician network is different. Promotional offer structure is different. This piece walks through the head-to-head comparison on the dimensions that matter for the consumer's actual decision: pricing, medication access, transparency, structural disclosure, and the fit-to-scenario matchup.
Corporate Structure and Disclosure
Both platforms are technology companies that connect consumers with independent licensed clinicians and dispensing pharmacy partners. Neither is a medical practice. Neither directly prescribes or dispenses medication. Both state this clearly in their terms.
Refills Health LLC is incorporated in Delaware and headquartered in Wilmington. The platform was founded in April 2025 with Matt Osborn as CEO. Refills' clinician network operates through Beluga Health, Bask Health, and Wasef Health. The dispensing pharmacy partner currently identified in Refills' terms is Perfect Rx Pharmacy in Texas, with a note that additional partners may be added.
SynergyRx operates a similar structure. Its clinician network operates through Lion MD, with named medical directors Dr. Ana Lisa Carr MD and Dr. Kelly Tenbrink MD providing leadership. SynergyRx's pharmacy partnerships are broader than Refills' currently disclosed partnership: SynergyRx names Belmar Pharmacy, Strive Pharmacy, Epiq Scripts, and Casa Pharma Rx as dispensing partners.
The structural disclosure read: both platforms operate above the category transparency average. Both name their clinician partner organization. Both disclose at least one dispensing pharmacy. SynergyRx's broader pharmacy network is the more diversified disclosure on the dispensing side. Refills' clinician network spans three named medical groups (Beluga, Bask, Wasef), which is more breadth on the clinician side.
Pricing — Where the Two Platforms Diverge Most
The pricing structures are different in ways that meaningfully affect consumer scenarios. The full Refills GLP-1 pricing breakdown covers the Refills tiers in detail; the short version is that Refills offers a $159 first-month promo, a $399 standard recurring rate, and a $6/day annual plan that averages roughly $180 per month when paid up front for 12 months.
SynergyRx's pricing is structured more as a flat tier. Compounded semaglutide injection starts at $199. Compounded tirzepatide injection starts at $349. Compounded oral options are listed at $299 (semaglutide) and $399 (tirzepatide). Brand-name options price higher: Wegovy and Mounjaro start at $947, Ozempic starts at $499. SynergyRx's pricing structure is less promo-heavy; the consumer sees the recurring rate from the start.
The pricing comparison on compounded semaglutide injection — the headline product on both platforms:
Refills: $159 first month (promotional), then $399 monthly standard or roughly $180/month equivalent on the 12-month annual plan.
SynergyRx: Starting at $199 per month with no documented promotional first-month rate.
What that means in practice: the cheapest first-month entry on Refills ($159) is more aggressive than the cheapest first-month entry on SynergyRx ($199). The cheapest ongoing month-to-month rate on Refills ($180 equivalent on annual plan) is comparable to the SynergyRx starting rate ($199). The non-annual recurring rate on Refills ($399) is meaningfully higher than the SynergyRx starting rate. The consumer who wants the lowest possible long-term cost without an annual commitment may find SynergyRx structurally better. The consumer who wants the lowest possible first-month entry to test the platform may find Refills structurally better. The consumer who is committed to annual prepayment finds the two platforms close on long-term cost.
Medication Options Available
Both platforms list both compounded and brand-name GLP-1 options. The breadth of medication options is broadly similar.
Refills lists access to compounded Personalized GLP-1 (compounded semaglutide injection) and brand-name Ozempic, Wegovy, Zepbound, and Saxenda. Refills also operates outside the GLP-1 weight management category, with offerings in better intimacy (sildenafil, tadalafil, Viagra, Cialis), daily health (NAD+, sermorelin, methylene blue), and hair growth (oral finasteride, oral minoxidil, finasteride-and-minoxidil topical spray). For the GLP-1-specific consumer, the cross-category breadth is not directly relevant; for a consumer interested in multiple categories from one platform, Refills' broader catalog is meaningful.
SynergyRx lists access to compounded semaglutide (injection and oral dissolving tablet), compounded tirzepatide (injection and oral dissolving tablet), and brand-name Ozempic, Wegovy, and Mounjaro. SynergyRx is more focused on weight management than Refills, with less cross-category catalog. The oral compounded options (semaglutide and tirzepatide oral dissolving tablets) are more prominently positioned on SynergyRx; Refills' compounded option is positioned as injection.
For a consumer specifically interested in oral compounded GLP-1, SynergyRx is the more direct fit. For a consumer specifically interested in injectable compounded GLP-1, both platforms compete directly. For a consumer interested in tirzepatide specifically, both platforms list it; SynergyRx's pricing on compounded tirzepatide ($349 starting for injection) is documented more prominently than Refills'.
Clinician Network and Intake Process
Both platforms route intake through licensed clinicians. Both states the clinician makes the prescribing decision; the platform does not. Both follow established medical protocols for GLP-1 prescribing eligibility — typically BMI 30 or higher, or 27 or higher with a qualifying weight-related condition.
The intake process is broadly similar across both: medical history, current medications, allergies, weight history, treatment goals, contraindication screening (including MTC and MEN 2 history, pancreatitis history, and other clinically relevant items). The structural intake quality is comparable.
SynergyRx names its medical directors specifically — Dr. Ana Lisa Carr MD (NPI: 1689841744) and Dr. Kelly Tenbrink MD (NPI: 1346482684) — which is a level of specific named-clinician disclosure that is unusual in the category. Refills names its clinician partner organizations (Beluga, Bask, Wasef) without naming individual medical directors at the platform level. SynergyRx's specific NPI-level disclosure is the more granular transparency on the clinician side.
Pharmacy Network and Fulfillment
SynergyRx's broader pharmacy network — four named partners (Belmar, Strive, Epiq Scripts, Casa Pharma Rx) — provides more redundancy and potentially more flexibility on fulfillment than Refills' current single-partner disclosure (Perfect Rx Pharmacy in Texas, with a note that more may be added). Diversified pharmacy networks reduce single-point-of-failure risk if any one pharmacy experiences supply issues, regulatory action, or operational problems.
Both platforms allow patients to direct prescriptions to a pharmacy of their choosing under their respective terms. The platform price covers in-network fulfillment only; out-of-network pharmacies are paid directly by the patient.
Both platforms reference shipping that is included in the program price. Refills documents three-to-five-day standard shipping with overnight shipping referenced on some pages. SynergyRx documents shipping included in the price without specific timing disclosure.
The FDA Compounded Disclaimer on Both Platforms
Both platforms display the standard regulatory disclaimer: compounded medications dispensed are not FDA-approved finished drug products and have not been evaluated by the FDA for safety, quality, or efficacy. The disclaimer language is materially equivalent on both platforms. Both platforms identify their dispensing pharmacy partners as licensed and inspected by State Boards of Pharmacy.
The structural compounded medication context — what the disclaimer means in practice and how the regulatory framework actually works — is covered in our editorial explainer on how compounded semaglutide telehealth works. The substantive read on either platform is the same: the consumer is buying a state-regulated preparation of a well-studied active molecule, prescribed by a licensed clinician, but not the same finished product the FDA reviewed. That regulatory context applies equally to both platforms.
Cancellation and Consumer Protection
Both platforms operate on subscription models with online cancellation through the user dashboard. Both follow the standard regulatory rule that prescription medications cannot be returned once dispensed.
Refills' specific window: the consumer can cancel before the prescription is sent to the pharmacy, after which the order's payment is final. SynergyRx operates a comparable window with similar mechanics. Neither platform's cancellation flexibility is materially different from the other on standard month-to-month plans.
Annual plan refund mechanics on both platforms are subject to how much medication has already been dispensed. Refills' $6/day annual plan and any equivalent SynergyRx multi-month commitment carry similar refund constraints once medication has been routed to the pharmacy.
Which Platform Fits Which Consumer Scenario
The clearest fit-to-scenario reading from the head-to-head comparison:
Refills fits the consumer testing GLP-1 access at low first-month commitment. The $159 promo is the most aggressive entry rate on the comparison. For someone uncertain whether they'll continue past month one, the lower entry cost reduces financial exposure during the trial period. Refills also fits the consumer who is highly confident in long-term commitment and willing to commit to or finance the annual plan, since the annual rate averages near the lowest sustained rate available.
SynergyRx fits the consumer wanting consistent month-to-month pricing without an annual commitment. The $199 starting rate without a promo step-up is more predictable across the first six to twelve months than Refills' $159-to-$399 transition. SynergyRx also fits the consumer specifically interested in compounded oral dissolving tablet options, which are more prominently positioned in SynergyRx's product line.
Either platform fits the consumer who wants both compounded and brand-name access. Both list brand-name Ozempic, Wegovy, and Mounjaro at broadly comparable pricing.
Neither platform fits the consumer with complex medical history requiring extensive coordinated care. Direct-to-consumer compounded GLP-1 telehealth is structurally suited for healthier patients seeking convenient access to a specific therapy. Patients with significant comorbidities, complex medication interactions, or insurance-covered GLP-1 access are typically better served by traditional in-person care or insurance-routed treatment paths. Our piece on Refills GLP-1 side effects and safety covers the contraindications and clinical scenarios where telehealth platforms generally are not the optimal fit.
The Honest Editorial Takeaway
Refills and SynergyRx are both competent compounded GLP-1 telehealth platforms operating with above-average structural transparency for the category. Neither is markedly worse than the other on any dimension. The differences live in pricing structure, pharmacy network breadth, and clinician disclosure specifics — not in fundamental quality of the offering.
The right choice for any individual depends on which structural feature matters most to that consumer. Lowest first-month entry: Refills. Most consistent ongoing month-to-month rate without annual commitment: SynergyRx. Broadest dispensing pharmacy network: SynergyRx. Most named-clinician disclosure: SynergyRx (NPI-level). Broadest cross-category catalog beyond GLP-1: Refills. Lowest sustained rate with annual commitment: Refills (slight edge).
For the full per-platform editorial reads, see our Refills GLP-1 review and the SynergyRx GLP-1 review. Broader category context lives at our Telehealth Platform Reviews hub, with adjacent weight management coverage at the Weight Management hub.
Whichever platform fits the individual consumer's specific scenario, the underlying clinical decision — whether GLP-1 therapy is appropriate at all — is a conversation between that consumer and a licensed healthcare provider. The platforms are delivery mechanisms. The clinical relationship is what makes treatment work.